Bristol -Myers Squibb News
BenchmarkJournal.com Free Analyst Review for BMY, ACF, FRE, TD, SWY and CBB
BenchmarkJournal.com Free Analyst Review for BMY, ACF, FRE, TD, SWY and CBB
SYS-CON Media - 23 minutes ago
LONDON -- (Marketwire) -- 11/06/09 -- Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear ...
ZymoGenetics Reports Third Quarter 2009 Financial Results
ZymoGenetics Reports Third Quarter 2009 Financial Results
Reuters - 23 minutes ago
http://www.businesswire.com/news/home/20091105005265/en Increased revenues and reduced expenses drive substantial improvement in quarterly net loss RECOTHROM sales increase to $8.5 million ...
InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
Reuters - 2 hours ago
WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for ...
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
Repligen Reports Second Quarter Fiscal Year 2010 Financial Results
PharmaLive.com - 15 minutes ago
WALTHAM, MA – November 5, 2009 – Repligen Corporation (NASDAQ: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was ...
A Cure for Cancer?
A Cure for Cancer?
CNBC - Nov 3, 2009
Bristol-Myers Squibb and Pfizer are “the most conservative ways to play the war against cancer,” Cramer said Monday. Both companies own strong drug pipelines, the stocks are cheap, and the share ...
Zyngenia, Inc. Raises $10 Million in Series A Funding
Zyngenia, Inc. Raises $10 Million in Series A Funding
Reuters - 1 hour ago
- Next-Generation Biotherapeutics Company Appoints Board of Directors, Management Team - ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on ...
